Evidence map›Paper›PMID 37095184›Full record

ArticleBritish journal of cancer2023

Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.

Jessica Pougoue Ketchemen, Hanan Babeker, Anjong Florence Tikum, Anand Krishnan Nambisan, Fabrice Ngoh Njotu, Emmanuel Nwangele, Humphrey Fonge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Potency and safety of novel [British journal of cancer · 2026
    Article
  2. [Breast cancer research : BCR · 2026
    Article
  3. Preclinical characterization of 3p-C-DEPAEJNMMI radiopharmacy and chemistry · 2025
    Article
  4. Article
  5. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  6. Effectiveness of [European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica Pougoue KetchemenDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Hanan BabekerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Anjong Florence TikumDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Anand Krishnan NambisanDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Fabrice Ngoh NjotuDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Emmanuel NwangeleDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Humphrey FongeDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. humphrey.fonge@usask.ca.ORCID http://orcid.org/0000-0001-9388-6872

Funding

CIHR 408132CIHR 437660
6 · The paper itself

Abstract

backgroundHER2 is overexpressed in 25-30% of breast cancer. Multiple domains targeting of a receptor can have synergistic/additive therapeutic effects.

methodsTwo domain-specific ADCs trastuzumab-PEG

resultsThe ADCs had an average drug-to-antibody ratio of 3. Trastuzumab did not compete with [

conclusionUsing these biologics simultaneously as biparatopic theranostic agents has additive benefits.

Indexed as

NeoplasmsPrecision MedicineAnimalsErb-b2 Receptor Tyrosine KinasesMiceTissue DistributionTrastuzumabErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID37095184
PMCPMC10307858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.